Publication Name	World Journal of Clinical Urology
Manuscript ID	17162
Country	Canada

Received	2015-02-21 21:49
Peer-Review Started	2015-02-22 17:56
To Make the First Decision	2015-05-13 19:55
Return for Revision	2015-05-18 17:32
Revised	2015-05-29 04:57
Second Decision	2015-07-14 15:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-07-23 17:01
Articles in Press	2015-07-23 17:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-23 13:44
Publish the Manuscript Online	2015-11-30 08:45

ISSN	2219-2816 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Editorial
Article Title	Nothing like data showing significant death reduction can better support prostate cancer screening
Manuscript Source	Invited Manuscript
All Author List	Fernand Labrie
Funding Agency and Grant Number
Corresponding Author	Fernand Labrie, MD, PhD, Emeritus Professor, Research Center, the University Hospital of Quebec, Laval University, 2795 Laurier Blvd, Suite 500, Quebec G1V 4M7, Canada. fl@fernandlabrie.com
Key Words	Prostate cancer; Screening; Prostate-specific antigen; Early diagnosis; Early treatment
Core Tip	The wide use of prostate-specific antigen for screening of prostate cancer is a major issue preventing the recruitment of true unscreened controls in studies on prostate cancer screening. This is why only studies performed some time ago can meet this requirement of a small contamination of the control group. The European Randomized Study on Screening for Prostate Cancer had a contamination of 23%-40%, thus permitting to see, at 13 years of follow-up, a 21% decrease in prostate cancer deaths in the screened group compared to no screening. The earlier Quebec trial had a contamination of only 7% with a 62% dec-rease in death from prostate cancer at a median follow-up of 7.9 years. A contamination of 85% of the control group prevented the United States PLCO trial from providing reliable data. The data obtained in the European and Quebec trials are strong arguments for a major positive impact of early diagnosis which needs screening for a successful fight against prostate cancer.
Publish Date	2015-11-30 08:45
Citation	Labrie F. Nothing like data showing significant death reduction can better support prostate cancer screening. World J Clin Urol 2015; 4(3): 97-99
URL	http://www.wjgnet.com/2219-2816/full/v4/i3/97.htm
DOI	http://dx.doi.org/10.5410/wjcu.v4.i3.97

Full Article (PDF)	WJCU-4-97.pdf
Full Article (Word)	WJCU-4-97.doc
Manuscript File	17162-Review.docx
Answering Reviewers	17162-Answering reviewers.pdf
Audio Core Tip	17162-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17162-Conflict-of-interest statement.pdf
Copyright License Agreement	17162-Copyright assignment.pdf
Peer-review Report	17162-Peer-review(s).pdf
Scientific Misconduct Check	17162-Scientific misconduct check.pdf
Scientific Editor Work List	17162-Scientific editor work list.pdf